| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Kyle Carver is Chief Financial Officer at EVMN. Kyle Carver's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $358K at current prices.
The EVMN filings lean toward selling, a net 17,175 shares.
Kyle Carver has 6 Form 4 filings on record from November 2025 to July 2026, all as Chief Financial Officer at Evommune (EVMN), 2025–2026.
The 7 reported transactions were 2 option or other derivative awards, 1 open-market purchase, 1 option exercise and 1 open-market sale, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $13K and 1 sale worth about $415K.
The only open-market purchase was 1,000 shares of EVMN at an average $13.26 on July 8, 2026, about $13K.
The only open-market sale was 18,175 shares of EVMN at an average $22.84 on May 28, 2026, about $415K.